<h4>Objectives</h4>To investigate the specific strengths of MRI and PET components in <sup>68</sup>Ga-PSMA-11 PET/MRI for staging of patients with biochemically recurrent prostate cancer (PCa).<h4>Methods</h4>Patients with biochemical recurrence of PCa and contrast-enhanced whole-body <sup>68</sup>Ga-PSMA-11 PET/MRI including a dedicated pelvic multiparametric MRI were included in this retrospective study. Here, FOLH1 is linked to prostate cancer.